TREATMENT OF GRAVES' OPHTHALMOPATHY WITH A PPAR-Ɣ ANTAGONIST AND COX-2 INHIBITOR ( SODIUM DICLOFENAC ) : A CRITICAL REVIEW

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: SUN 432-458-Thyroid Autoimmunity
Basic/Clinical
Sunday, June 16, 2013: 1:45 PM-3:45 PM
Expo Halls ABC (Moscone Center)

Poster Board SUN-438
Janete P Moura*1, Lidia Y Mimura2 and Walter Bloise3
1FMUSP, Sao Paulo, Brazil, 2Hosp das Clinicas FMUSP, Sao Paulo, Brazil, 3Hosp das Clinicas Schl of Med, Sao Paulo, Brazil
BACKGROUND –  The expression of PPAR- γ  is increased in the  retro-ocular adipose tissue in active phase of GO. OBJETIVE - The aim of this study is to report  the current  evaluation of the role of sodium diclofenac in the treatment of Graves’ ophthalmopathy (GO). MATERIAL AND METHODS – 31 patients  with GO  were selected for the new treatment ,  25 finished the study  assigned in    two groups  according to the clinical activity score (CAS): Group I = 5-7, Group II = 2 -4 . Oral  diclofenac  50 mg was administered  every 12 hs,   for 3 to 12 months and omeprazole in case of gastric pain. The  drug was withdrawn    when the clinical signs and symptons desapeared  or when reached 12 months.   Renal function was checked every two months. Patients with CAS 2 was included when complaining of distressing ocular pain and diplopia. RESULTS –  The  age  of  patients ranged from: G I (n=6 ) - 31 to73 years old average of 47 . G II (n=25)– ranged from 24 to 66, average 41. The CAS ranged from 6.3 ±0.81 to 4.1±1.6  and  from 3.1± 0.73 to 1.68± 1.0, decreasing significantly   of  I and II groups respectively.  Hyperthyroidism present in 4 and 14 patients of  I and II respectively keeping . CONCLUSION – The  treatment of mild to  moderate    GO with diclofenac was effective. These results should be checked by a controlled study.

Nothing to Disclose: JPM, LYM, WB

*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm